ADELA | Publications

Adela’s genome-wide methylome enrichment platform offers an efficient, comprehensive, tissue-free approach to detect cancer based on its underlying biology. This single, scalable platform enables assay development across multiple cancers and treatment paradigms.

The platform leverages Adela’s patented cfMeDIP-seq technology to facilitate whole methylome capture in a nondegradative process. Selective isolation of methylated DNA streamlines sequencing, reducing cost while maintaining breadth of cancer signal.

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [father and child playing guitar]

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [magnifying glass icon]

Tissue-free

Not tumor biopsy required ensure access to testing for all patient

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [monitor icon]

6-10 Day TAT

Fast results support real-time clinical decisions

Adela Bio | Toronto, San Fransisco | A breakthrough approach to cancer detection [routine icon]

3T+ Genomic Datapoints

Growing methylation atlas enhances machine learning

One platform across the cancer care continuum.

publications library

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab

Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab

Identification of immunotherapy early treatment failure in non-small cell lung cancer (NSCLC) sing a novel cell-free DNA (cfDNA) tissue-agnostic genome-wide methylome enrichment assay

The development of a tissue-agnostic genome-wide methylome enrichment assay for lung cancer

Biological insights into tissue-agnostic plasma cfDNA methylation signature for surveillance of head and neck cancer recurrence

Clinical Validation of a Tissue-agnostic Genome-wide Methylome Enrichment MRD Assay for Head and Neck Cancers

Clinical validation of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies

Performance characteristics of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies

Analytical performance of a genome-wide methylome enrichment platform to detect minimal residual disease from plasma-derived cell-free DNA

The development of a tissue-agnostic genome-wide methylome enrichment MRD assay for applications across the cancer care continuum for head and neck malignancies

Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors

Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Pre-Analytic Variables and Quality Controls for Robust Processing of Plasma-Derived Cell-Free DNA (cfDNA) Using a Whole Methylome Enrichment Platform

Prognostic Performance of a Genome-Wide Methylome Enrichment Platform in Head and Neck Cancer

Evaluation of a Genome-Wide Methylome Enrichment Platform for Circulating Tumor DNA Quantification and Prognostic Performance in Renal Cell Carcinoma (RCC)

Development of a Genome-Wide Methylome Enrichment Platform for Multi-Cancer Early Detection

Cell-free DNA methylation-defined prognostic subgroups in small-cell lung cancer identified by leukocyte methylation subtraction

Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors

Sensitive and reproducible cell-free methylome quantification with synthetic spike-in controls

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes

Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA

Sensitive tumour detection and classification using plasma cell-free DNA methylomes